Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Elevance Health (NYSE:ELV) Stock Price

Key Points

• Deutsche Bank raised its price target on Elevance Health to $363 (from $332) while keeping a "hold" rating, implying roughly a 5% upside from the prior close.
• Elevance beat Q1 EPS and revenue (EPS $12.58 vs. $10.74 est.; revenue $49.49B vs. $48.21B) and raised FY‑2026 guidance, with management citing medical‑cost controls, AI‑driven discipline and higher investment income as drivers of margin improvement.
• A law firm has launched an investor investigation into potential securities‑law claims involving Elevance and senior management, creating a legal/regulatory overhang despite the positive operating results.

Elevance Health (NYSE:ELV - Get Free Report) had its price target increased by analysts at Deutsche Bank Aktiengesellschaft from $332.00 to $363.00 in a report issued on Thursday,MarketScreener reports. The firm presently has a "hold" rating on the stock. Deutsche Bank Aktiengesellschaft's price objective indicates a potential upside of 5.03% from the stock's previous close.

A number of other equities analysts also recently commented on ELV. Guggenheim reaffirmed a "buy" rating and set a $399.00 target price on shares of Elevance Health in a research note on Friday. Weiss Ratings cut shares of Elevance Health from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, February 2nd. UBS Group set a $400.00 price target on shares of Elevance Health in a research note on Thursday, January 29th. Royal Bank Of Canada downgraded shares of Elevance Health from an "outperform" rating to a "sector perform" rating and set a $358.00 price target for the company. in a research note on Tuesday, February 3rd. Finally, Wall Street Zen downgraded shares of Elevance Health from a "buy" rating to a "hold" rating in a research report on Sunday, February 8th. Eleven analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Elevance Health has a consensus rating of "Hold" and a consensus price target of $384.65.

Elevance Health Stock Performance

ELV stock traded down $0.67 during midday trading on Thursday, hitting $345.62. 159,449 shares of the stock traded hands, compared to its average volume of 1,858,392. The firm has a market cap of $75.92 billion, a P/E ratio of 14.67, a PEG ratio of 1.83 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.54. The stock's fifty day simple moving average is $309.00 and its 200-day simple moving average is $331.66. Elevance Health has a 1-year low of $273.71 and a 1-year high of $427.54.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company's revenue was up 1.5% compared to the same quarter last year. During the same period last year, the firm posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, analysts expect that Elevance Health will post 25.5 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. IFM Investors Pty Ltd lifted its holdings in shares of Elevance Health by 1.9% during the 1st quarter. IFM Investors Pty Ltd now owns 48,933 shares of the company's stock worth $14,325,000 after acquiring an additional 914 shares during the period. Premier Path Wealth Partners LLC grew its position in shares of Elevance Health by 17.0% during the first quarter. Premier Path Wealth Partners LLC now owns 993 shares of the company's stock worth $291,000 after buying an additional 144 shares in the last quarter. SJS Investment Consulting Inc. grew its position in shares of Elevance Health by 23.6% during the first quarter. SJS Investment Consulting Inc. now owns 868 shares of the company's stock worth $254,000 after buying an additional 166 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ boosted its holdings in Elevance Health by 1.3% in the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 74,278 shares of the company's stock worth $21,745,000 after purchasing an additional 968 shares during the period. Finally, 3Chopt Investment Partners LLC lifted its stake in Elevance Health by 20.2% in the first quarter. 3Chopt Investment Partners LLC now owns 708 shares of the company's stock valued at $207,000 after buying an additional 119 shares during the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 results and guidance lift sentiment — ELV reported better-than-expected Q1 EPS and raised its 2026 adjusted EPS outlook (targets 12% EPS growth in 2027), signaling stronger profitability and upward earnings momentum. Elevance raises 2026 adjusted EPS outlook
• Positive Sentiment: Management cites medical-cost controls and AI-driven operating discipline as drivers of margin expansion and a higher annual profit forecast — supports sustainable margin improvement. Health insurer Elevance raises annual profit forecast
• Positive Sentiment: Investment income helped EPS — rising net investment income materially boosted Q1 results, offsetting some membership pressure. ELV Beats Q1 on rising net investment income
• Positive Sentiment: Analyst support: Evercore raised its price target to $360, adding buy-side validation for the beat-and-raise story. Evercore raises price target on Elevance
• Positive Sentiment: Shareholder return: Board declared a quarterly dividend (supports income-oriented investors and reduces downside risk).
• Neutral Sentiment: Analyst stance mixed — Robert W. Baird raised its target to $331 but moved to a "neutral" rating, reflecting more cautious near-term expectations despite higher valuation work. Baird updates target and rating
• Neutral Sentiment: Operational caveat: Management noted membership declines; the topline impact is being offset by investment income and cost controls — watch membership trends for sustainability. Valuation and mixed Q1 draw attention
• Negative Sentiment: Legal risk: A law firm (Kirby McInerney LLP) has launched an investor investigation into potential securities-law claims involving Elevance and senior management — introduces regulatory/legal overhang and potential litigation risk. Investor alert: Kirby McInerney investigates Elevance

Elevance Health Company Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.